Anti-islet cell antibody
Anti-islet cell antibody (ICA) was first reported by Bottazzo in 1974. The target antigen is a component present in the cytoplasm or microsomes of islet cells, organ-specific, but species-specific, human islet cells The antibodies cross-reacted with islet cells of monkey, rat and guinea pigs. Normal people do not have this antibody. The positive rate of 40% to 50% in patients with diabetes onset is 15% to 20% in 5-10 years, especially in juvenile diabetes. This antibody primarily distinguishes between insulin-dependent diabetes mellitus (1DDM) and non-insulin-dependent diabetes mellitus (NIDDM). In the new ID-DM patients, the positive rate can reach more than 90%, and ICA positive in NIDDM patients can predict the possibility of IDDM.Basic Information
Specialist classification: Digestive examination classification: endocrine examination
Applicable gender: whether men and women apply fasting: fastingAnalysis results:
Positive in the initial diagnosis of insulin-dependent diabetes mellitus, the total positive rate was 31.2, up to 85% in the first two weeks of onset, and reduced to 50% in a few weeks; in non-insulin-dependent diabetes and "chemical" diabetes Humans, the positive rate is only 6.2% and 4.9%, so it can be used as a differential diagnosis basis for insulin-dependent and independent diabetes.Positive results may be diseases: considerations for diabetes
Forbidden before examination: Please inform the doctor about the recent medication and special physiological changes before the test.
1, do not eat too greasy, high-protein food the day before the blood, to avoid heavy drinking. The alcohol content in the blood directly affects the test results.
2. After 8 pm on the day before the medical examination, you should start fasting for 12 hours to avoid affecting the test results.
Requirements for examination: When taking blood, you should relax your mind, avoid the contraction of blood vessels caused by fear, and increase the difficulty of blood collection. Obtain serum samples and store at -20 degrees Celsius.Inspection process
Indirect immunofluorescence experimental principle: fluorescein is labeled on the corresponding antibody and directly reacts with the corresponding antigen.
In the first step, an unknown unlabeled antibody (sample to be tested) is added to a known antigen sample, and incubated at 37 ° C for 30 min in a wet box to sufficiently bind the antigen antibody, followed by washing to remove unbound antibody.
In the second step, a fluorescently labeled anti-globulin antibody or an anti-IgG, IgM antibody is added. If an antigen-antibody reaction occurs in the first step, the labeled anti-globulin antibody is further bound to the antigen-binding antibody, thereby enabling identification. Unknown antibody.Not suitable for the crowd
Inappropriate people: generally no special population.Adverse reactions and risks
There are no related complications and hazards.